CFA
HRTX icon

Cahill Financial Advisors’s Heron Therapeutics HRTX Stock Holding History

Cahill Financial Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-223
Closed -$2K – 455
2021
Q3 		$2K Buy
+223
New +$2.71K ﹤0.01% 783

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Cahill Financial Advisors's HRTX Position: Q4 2021 in Review

Cahill Financial Advisors sold out of Heron Therapeutics (HRTX) in Q4 2021, closing a stake of 223 shares — an estimated $2K sold.

Cahill Financial Advisors first reported a position in HRTX in Q3 2021 and held it in 1 quarter. The position peaked at $2K in Q3 2021. 200 funds tracked by Wall St. Rank hold HRTX as of Q4 2021.

  • Cahill Financial Advisors reported no remaining Heron Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Cahill Financial Advisors sold 223 Heron Therapeutics shares in Q4 2021, an estimated $2K.
  • Cahill Financial Advisors first reported a position in Heron Therapeutics in Q3 2021 and held it in 1 quarter.
  • Cahill Financial Advisors's Heron Therapeutics position peaked at $2K in Q3 2021.
  • 200 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2021.

Based on Cahill Financial Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.